Progress of cetuximab in treatment of squamous cell carcinoma of head and neck
10.3760/cma.j.cn115355-20240301-00093
- VernacularTitle:西妥昔单抗在头颈部鳞状细胞癌治疗中的研究进展
- Author:
Dongzhu YAN
1
;
Yixiong REN
;
Wenge CHEN
Author Information
1. 山西医科大学口腔医学院，太原 030001
- Publication Type:Journal Article
- Keywords:
Head and neck neoplasms;
Carcinoma, squamous cell;
Receptor, epidermal growth factor;
Molecular targeted therapy;
Cetuximab
- From:
Cancer Research and Clinic
2025;37(6):477-480
- CountryChina
- Language:Chinese
-
Abstract:
Cetuximab, a representative agent for targeted therapy of epidermal growth factor receptor, is widely used in the treatment of cancers including head and neck squamous cell carcinoma. However, due to the side effects associated with cetuximab and the comorbidities developed in patients with head and neck squamous cell carcinoma during the treatment, there are certain difficulties in its clinical application. This article summarizes the relevant mechanisms and research progress of cetuximab in the treatment of squamous cell carcinoma of head and neck, providing insights and clinical basis for the formulation of treatment plans.
